Hims reports revenue miss and surprise loss in Q1
The company reported earnings results on Monday.
Hims & Hers fell in after-hours trading after it reported a surprise loss and revenue numbers that missed Wall Street expectations as its shift away from knock-off weight loss drugs weighs on its margins.
For the first three months of 2026, the company reported:
$608 million in revenue, compared to the $616.8 million analysts polled by FactSet were expecting.
A loss per share of $0.40, compared to an expected profit of $0.03. Hims saw its margins shrink this quarter and also faced several one-time costs. Hims CFO Yemi Okupe told analysts he expects the company to return to profitability in 2027.
For the full year in 2026, the company expects:
Revenue to hit between $2.8 billion and $3.0 billion, higher than its previous guidance of $2.7 billion to $2.9 billion and in line with the $2.7 billion analysts are penciling in.
Adjusted EBITDA between $275 million and $350 million, higher than its previous forecast of $300 million to $375 million with a lower midpoint than the $317 million analysts are expecting.
The earnings report covers a very dramatic period for the company.
In February, the company rolled out a copy of Novo Nordisk’s Wegovy pill, which it eventually pulled after being sued by the drugmaker and getting scrutiny from regulators. It now partners with Novo to distribute its branded GLP-1s in exchange for dropping its cheaper, higher-margin knockoffs. CEO Andrew Dudum told analysts that the company had sent 125,000 shipments for Wegovy products so far.
Hims spent $33 million on that restructuring, which “consists of inventory write-downs and third-party costs,” the company said. Hims also said it spent $15 million in the quarter on “legal settlement costs.”
Hims has gained a tailwind in recent months after the Food and Drug Administration announced that it would ease restrictions on 12 peptides, which Hims and other consumer health companies are eager to get in on. Dudum didn’t give a firm timeline on rolling out that segment but said “we likely won’t be first to market.”
Executives put focus on its newer segments, such as hormone treatments, as well as its growing international presence. The company said its testosterone segment is now serving “tens of thousands” of people.
.jpg?auto=compress%2Cformat&cs=srgb&fit=max&w=3840)